5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds

Page 1 of 5

In this article, we will take a look at the 5 most undervalued biotech stocks to buy according to hedge funds. To see more such companies, go directly to 11 Most Undervalued Biotech Stocks To Buy According To Hedge Funds.

5. iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Number of Hedge Fund Holders: 20

PE Ratio as of February 8: 3.09

iTeos Therapeutics, Inc. (NASDAQ:ITOS) is a Massachusetts-based clinical-stage biopharmaceutical company involved in the development of immuno-oncology therapeutics for patients. iTeos Therapeutics, Inc. (NASDAQ:ITOS) has a PE ratio of 3.09 as of February 8. In November, iTeos Therapeutics, Inc. (NASDAQ:ITOS) posted its third-quarter results. GAAP EPS in the quarter came in at $0.03, while cash and cash equivalents came in at $752.2 million as of the end of the third quarter.

As of the end of the third quarter of 2022, 20 hedge funds tracked by Insider Monkey reported owning stakes in iTeos Therapeutics, Inc. (NASDAQ:ITOS). The net worth of these stakes was Peter Kolchinsky’s RA Capital Management, with an $84 million stake.

Page 1 of 5